TWiV 686: COVID-19 clinical update #38 with Dr. Daniel Griffin
Nov 28, 2020•34 min•Ep. 686
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Daniel Griffin provides his weekly clinical report on COVID-19, including new post-exposure guidelines from CDC, clinical trials of Remdesivir and convalescent plasma, FDA EUA for baricitinib and Regeneron's monoclonal antibody and more.
Hosts: Daniel Griffin and Vincent RacanielloSubscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- WHO Solidarity trial for Remdesivir and other drugs (medRxiv)
- EUA for Baricitinib (FDA)
- EUA for Casirivimab and Imdevimab (FDA)
- RCT: No benefit of convalescent plasma (NEJM)
- Letters read on TWiV 686
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
For the best experience, listen in Metacast app for iOS or Android